Catalysts / AKTS
Upcoming FDA decisions and readouts we track for Aktis Oncology, each with the filing that announced it.
FreeBioList tracks 2 upcoming catalysts for Aktis Oncology (AKTS, listed on Nasdaq). They cover 2 programmes: AKY-1189 (Urothelial and Nectin-4 expressing solid tumours (radiopharmaceutical)) and AKY-2519 (Metastatic castration-resistant prostate cancer (B7-H3 radiopharmaceutical)).
First on the list: the Phase 1B readout for AKY-1189 (Urothelial and Nectin-4 expressing solid tumours (radiopharmaceutical)), guided by the company to Q1 2027. By stage, the upcoming rows are 2 Phase 1B readouts.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Aktis Oncology AKTS · Nasdaq | AKY-1189 | Urothelial and Nectin-4 expressing solid tumours (radiopharmaceutical) | Q1 2027 company guidance |
Phase 1B readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Aktis Oncology AKTS · Nasdaq | AKY-2519 | Metastatic castration-resistant prostate cancer (B7-H3 radiopharmaceutical) | 2027 company guidance |
Phase 1B readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList